Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form
Reexamination Certificate
2003-01-06
2004-03-02
Nutter, Nathan M. (Department: 1711)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
C424S422000, C424S424000, C424S425000, C424S426000, C424S443000, C424S444000, C514S021800, C514S054000, C514S055000, C514S056000, C606S214000, C606S215000
Reexamination Certificate
active
06699484
ABSTRACT:
BACKGROUND OF THE INVENTION
Fibrin glues, also called fibrin adhesives or sealants, are known for uses in a medical context. Generally, a fibrin glue is obtained by admixing fibrinogen and thrombin containing components. The components are mixed, allowing the thrombin to convert the fibrinogen to fibrin monomers. A number of methods for the production of fibrin glues are known, as illustrated by: Thompson et al., “Fibrin Glue: A Review of Its Preparation, Efficacy, and Adverse Effects as a Topical Hemostat,”
Drug Intelligence and Clinical Pharmacy
22: 946-52 (1988); Brennan, “Fibrin Glue,”
Blood Reviews
5: 240-44 (1991); Stechison, “Rapid Polymerizing Fibrin Glue from Autologous or Single Donor Blood: Preparation and Indications,”
J. Neurosurgery
76: 626-28 (1992); and Toma et al. “Autologous Fibnn Glue in the Repair of Dural Defects in Craniofacial Resections,”
J. Laryngology and Otology
106: 356-57 (1992). (The respective contents of publications cited in this description hereby are incorporated by reference.)
The fibrinogen component of the composition can be obtained by conventional methodology. Examples of such methods include centrifugation, cryoprecipitation and precipitation using polyethylene glycol, ether, ethanol, glycine or ammonium sulfate. Methods of obtaining suitable fibrinogen are disclosed, for example, by Brennan, “Fibrin Glue,”
Blood Reviews
5: 240-244 (1991). Further examples of fibrin components are disclosed in U.S. Pat. Nos. 5,290,918 and 5,395,923.
The thrombin component of the composition is also well known in the art and can be obtained by conventional methods, including recombinant methods. Bovine and human derived thrombins are illustrative of available thrombins well known in the art.
Application of the fibrin glue can be accomplished in a number of ways known in the art. In one method, the admixture is drawn into a syringe and ejected via an appropriate sized needle. In another method a double barrel syringe is used. Other conventional techniques employ a microdrop delivery system, a spray application via a multi-channel catheter which is fixed to a pressurized gas source, or a carrier, such as collagen fleece, dura, or a graft. Additionally, a number of special applicators are commercially available.
Numerous uses for fibrin glues are known. Fibrin glues are used in a variety of medical procedures as hemostatic agents, sealants and adhesives. For example, see Chisholm et al., “Fibrin Sealant as a Plug for the Post Liver Biopsy Needle Track,”
Clinical Radiology
40: 627-28 (1989); Toma et al., “Autologous Fibrin Glue in the Repair of Dural Defects in Craniofacial Resections,”
J. Latyngology and Otology
106: 356-57 (1992); Kjaergard et al., “Autologous Fibrin Glue Preparation and Clinical Use in Thoracic Surgery,”
Eur. J. Cardio-Thorc. Surg.
6: 52-54 (1992); Thompson et al., “Fibrin Glue: A Review of Its Preparation, Efficacy, and Adverse Effects as a Topical Hemostat,”
Drug Intelligence and Clinical Pharmacy
22: 946-52 (1988); Brennan, “Fibrin Glue,”
Blood Reviews
5: 240-44 (1991).
Available fibrin glues, however, have a number of significant disadvantages. The fibrinogen and thrombin components must be mixed just prior to use. Admixing too early can result in clotting before it can be applied. Thus, medical professionals are forced to divert their attention for a significant amount of time to prepare the fibrin glue. Early clotting also causes problems in application, such as clogging in the needle or applicator. Additionally, preparation of the fibrin glue can involve complex and time-consuming efforts to establish a workable mix of the fibrinogen and thrombin components. Still further, available fibrin glues may insufficiently adhere to the wound, or may provide inadequate strength to the wound during the healing process.
BRIEF SUMMARY OF THE INVENTION
The present invention relates to a fibrin glue composition comprising a biocompatible and bioabsorbable material, i.e., a biomaterial, of a hyaluronic acid (HA) or a hyaluronic acid derivative. The material may be either nonfilamentous (a film) or a woven or nonwoven fabric. The fibrin glues of the present invention have fibrinogen and thrombin applied to or chemically bonded to the HA or HA derivative material. Additional elements also can be applied to the material. Exemplary of these additional elements are further coagulation factors, anti-fibrinolytics, stabilizers and biologically active substances.
The fibrinogen, thrombin and, optionally, other elements can be applied to the hyaluronic acid derivative film as a dry preparation, as an aqueous or nonaqueous preparation, or as a combination thereof.
BRIEF DESCRIPTION OF THE DRAWING(S)
Not Applicable
REFERENCES:
patent: 4650678 (1987-03-01), Fuhge et al.
patent: 4851521 (1989-07-01), della Valle et al.
patent: 4909251 (1990-03-01), Seelich
patent: 4957744 (1990-09-01), della Valle
patent: 5202431 (1993-04-01), della Valle
patent: 5290918 (1994-03-01), Bui-Khac
patent: 5336767 (1994-08-01), della Valle et al.
patent: 5395923 (1995-03-01), Bui-Khac et al.
patent: 5631011 (1997-05-01), Waldstrom
patent: 5773033 (1998-06-01), Cochrum et al.
patent: 6503527 (2003-01-01), Whitmore et al.
patent: 0 216 453 (1987-04-01), None
patent: WO96/17631 (1996-06-01), None
Andrião-Escarso, S., et al., “Isolation and Characterization of a New Clotting Factor FromBothrops Jararacussu(Jararacucu) Venom”.Toxicon, 35: 1043-1052 (1997).
Benedetti, L., “New Biomaterials from Hyaluronic Acid”,Medical Device Technology, 32-37 (Nov. 1994).
Brennan, M., “Fibrin Glue”,Blood Reviews, 5: 240-244 (1991).
Chisholm, R., et al., “Fibrin Sealant as a Plug for the Post Liver Biopsy Needle Track”,Clinical Radiology, 40: 627-628 (1989).
Dascombe, W., et al., “Application of Thrombin Based Fibrin Glue and Non-Thrombin Based Batroxobin Glue on Intact Human Blood Vessels: Evidence for Transmural Thrombin Activity”,Thromb. Haemost., 78:947-951 (1997).
Fo{haeck over (r)}tová, H., et al., “Simultaneous Isolation of Protein C Activator, Fibrin Clot Promoting Enzyme (Fiprozyme) and Phospholipase A2from the Venom of the Southern Copperhead Snake”,J. Chromatogr. S. Biomed Appl. 694: 49-53 (1997).
Hahn, B., et al., “Purification and Molecular Cloning of Calobin, a Thrombin-Like Enzyme from Agkistrodon Caliginosus (Korean Viper)”,J. Biochem. (Tokyo) 119: 835-843 (1996).
Kjaergard, H., et al., “Autologous Fibrin Glue Preparation and Clinical Use in Thoracic Surgery”,Eur., J. Cardio-Thorc. Surg. 6: 52-54 (1992).
Rathke T., et al., “Review of Chitin and Chitosan as Fiber and Film Formers”,Rev.
Macromol. Chem. Phys. C34 (3): 375-437 (1994).
Stechison, M., “Rapid Polymerizing Fibrin Glue from Autologous or Single-Donor Blood: Preparation and Indications”,J. Neurosurgery76: 626-628 (1992).
Thompson, D., et al., “Fibrin Glue: A Review of Its Preparation, Efficacy, and Adverse Effects as a Topical Hemostat”,Drug Intelligence and Clinical Pharmacy, 22:946-952 (1998).
Toma, A., et al., “Autologous Fibrin Glue in the Repair of Dural Defects in Craniofacial Resections”,J. Laryngology and Otology, 106: 356-357 (1992).
Paquin Marc R.
Whitmore Elaine
Haemacure Corporation
Michael & Best & Friedrich LLP
Nutter Nathan M.
Welch, Esq. Teresa J.
Yager, Esq. Charlene L.
LandOfFree
Fibrin sealants or adhesives comprising a hyaluronic acid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fibrin sealants or adhesives comprising a hyaluronic acid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fibrin sealants or adhesives comprising a hyaluronic acid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3255605